Insider Trading activities of Audentes Therapeutics, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Audentes Therapeutics, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Audentes Therapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Audentes Therapeutics, Inc. since 2005. The reporting company's ticker symbol is BOLD. The reporting company's CIK number is 1628738.
The total value of stock buying since 2005 is $11,600,008.
The total value of stock sales since 2005 is $22,542,730.
The total value of stock option exercises since 2005 is $143,624.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Audentes Therapeutics, Inc. (BOLD).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-12 0 $0 8,000 $229,744 8,000 $6,320
2017-11 0 $0 10,000 $268,990 10,000 $21,900
2017-10 0 $0 25,000 $698,075 10,000 $7,800
2017-09 0 $0 731,500 $20,551,505 25,500 $30,505
2017-08 0 $0 10,000 $200,000 10,000 $21,900
2017-07 0 $0 15,000 $300,056 0 $0
2017-06 0 $0 15,000 $294,360 0 $0
2017-05 0 $0 0 $0 20,000 $55,199
2017-04 172,413 $2,499,988 0 $0 0 $0
2016-07 606,668 $9,100,020 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Audentes Therapeutics, Inc. insiders (BOLD)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-12-01 Prasad Suyash (Senior VP & Chief Med Officer) Sale 8,000 28.72 229,744
2017-12-01 Prasad Suyash (Senior VP & Chief Med Officer) Option Ex 8,000 .79 6,320
2017-11-16 Newman Mary (SVP, Regulatory Affairs) Sale 10,000 26.90 268,990
2017-11-16 Newman Mary (SVP, Regulatory Affairs) Option Ex 10,000 2.19 21,900
2017-10-02 Patterson Matthew R (President & CEO) Sale 25,000 27.92 698,075
2017-10-02 Patterson Matthew R (President & CEO) Option Ex 10,000 .78 7,800
2017-09-29 Lange Louis G (Director) Sale 11,000 28.72 315,942
2017-09-29 Isaly Samuel D Sale 672,000 28.25 18,984,000
2017-09-27 Nagler David (SVP, HR & Corp. Affairs) Sale 3,750 30.00 112,500
2017-09-27 Nagler David (SVP, HR & Corp. Affairs) Option Ex 3,750 2.19 8,193
2017-09-25 Lange Louis G (Director) Sale 18,000 28.42 511,524
2017-09-18 Patterson Matthew R (President & CEO) Sale 8,458 25.07 212,008
2017-09-18 Patterson Matthew R (President & CEO) Option Ex 8,458 .78 6,597
2017-09-15 Nagler David (SVP, HR & Corp. Affairs) Sale 3,750 25.00 93,750
2017-09-15 Nagler David (SVP, HR & Corp. Affairs) Option Ex 3,750 2.19 8,193
2017-09-15 Patterson Matthew R (President & CEO) Sale 1,542 25.00 38,551
2017-09-15 Patterson Matthew R (President & CEO) Option Ex 1,542 .78 1,202
2017-09-07 Isaly Samuel D Sale 5,000 22.35 111,750
2017-09-01 Prasad Suyash (Senior VP & Chief Med Officer) Sale 8,000 21.43 171,480
2017-09-01 Prasad Suyash (Senior VP & Chief Med Officer) Option Ex 8,000 .79 6,320
2017-08-24 Newman Mary (SVP, Regulatory Affairs) Sale 10,000 20.00 200,000
2017-08-24 Newman Mary (SVP, Regulatory Affairs) Option Ex 10,000 2.19 21,900
2017-07-13 Patterson Matthew R (President & CEO) Sale 12,150 20.00 243,048
2017-07-12 Patterson Matthew R (President & CEO) Sale 2,850 20.00 57,008
2017-06-26 Lange Louis G (Director) Sale 15,000 19.62 294,360
2017-05-31 Holles Natalie C. (Senior Vice President, COO) Option Ex 20,000 2.76 55,199
2017-04-24 Rocklage Scott M (Other) Buy 172,413 14.50 2,499,988
2016-07-25 Woiwode Thomas (Director) Buy 35,000 15.00 525,000
2016-07-25 Deerfield Private Design Fund Iii, L.p. Buy 400,000 15.00 6,000,000
2016-07-25 5am Partners Iii, Llc (10% Owner) Buy 70,000 15.00 1,050,000
2016-07-25 Versant Ventures Iv, Llc (10% Owner) Buy 35,000 15.00 525,000
2016-07-25 Silverstein Jonathan (Director) Buy 33,334 15.00 500,010
2016-07-25 Orbimed Advisors Llc (Director) Buy 33,334 15.00 500,010

Insider trading activities including stock purchases, stock sales, and option exercises of BOLD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Audentes Therapeutics, Inc. (symbol BOLD, CIK number 1628738) see the Securities and Exchange Commission (SEC) website.